Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . 康 龙 化成 PHARMARON Pharmaron Beijing Co. , Ltd. 康 龍 化成 ( 北京 ) 新藥 技術 股份有限公司 ( a joint stock company incorporated in the People's Republic of China with limited liability ) ( Stock Code : 3759 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2026 FINANCIAL SUMMARY AND HIGHLIGHTS Six months ended June 30 , 2026 RMB'000 2025 RMB'000 Change % Revenue 7,595,424 6,440,951 17.9 Gross profit 2,474,869 2,172,201 13.9 Profit attributable to owners of the parent Non - IFRSS adjusted net profit attributable to 750,194 701,396 7.0 owners of the parent 909,013 755,701 20.3 Net cash flows generated from operating activities 1,084,645 1,408,277 ( 23.0 ) During the Reporting Period , the Group recorded aggregate revenue of approximately RMB7,595.4 million , representing an increase of approximately RMB1,154.5 million , or 17.9 % , as compared to the six months ended June 30 , 2025 . During the Reporting Period , the profit attributable to owners of the parent was approximately RMB750.2 million , representing an increase of approximately 7.0 % as compared to the six months ended June 30 , 2025 . During the Reporting Period , the net cash flows generated from operating activities were approximately RMB1,084.6 million , representing a decrease of approximately 23.0 % as compared to the six months ended June 30 , 2025 . The Board resolved not to declare any interim dividend for the six months ended June 30 , 2026 . The Board of Pharmaron Beijing Co. , Ltd. is pleased to announce the unaudited interim results of the Group for the six months ended June 30 , 2026 , together with the comparative figures for the corresponding period in 2025 .